@article{Zhang_Pitchiaya_Cieslik-Analy_the_andro-2018,
author = {Zhang, Yajia and Pitchiaya, Sethuramasundaram and Cieslik, 
          Marcin and Niknafs, Yashar S. and Tien, Jean C-Y and Hosono, 
          Yasuyuki and Iyer, Matthew K. and Yazdani, Sahr and 
          Subramaniam, Shruthi and Shukla, Sudhanshu K. and Jiang, Xia 
          and Wang, Lisha and Liu, Tzu-Ying and Uhl, Michael and 
          Gawronski, Alexander R. and Qiao, Yuanyuan and Xiao, Lanbo 
          and Dhanasekaran, Saravana M. and Juckette, Kristin M. and 
          Kunju, Lakshmi P. and Cao, Xuhong and Patel, Utsav and 
          Batish, Mona and Shukla, Girish C. and Paulsen, Michelle T. 
          and Ljungman, Mats and Jiang, Hui and Mehra, Rohit and 
          Backofen, Rolf and Sahinalp, Cenk S. and Freier, Susan M. 
          and Watt, Andrew T. and Guo, Shuling and Wei, John T. and 
          Feng, Felix Y. and Malik, Rohit and Chinnaiyan, Arul M.},
title = {Analysis of the androgen receptor-regulated {lncRNA} 
         landscape identifies a role for {ARLNC1} in prostate cancer 
         progression},
journal = {Nat Genet},
year = {2018},
doi = {10.1038/s41588-018-0120-1},
volume = {50},
user = {backofen},
pmid = {29808028},
pages = {814-824},
number = {6},
issn = {1061-4036},
abstract = {The androgen receptor (AR) plays a critical role in the 
            development of the normal prostate as well as prostate 
            cancer. Using an integrative transcriptomic analysis of 
            prostate cancer cell lines and tissues, we identified ARLNC1 
            (AR-regulated long noncoding RNA 1) as an important long 
            noncoding RNA that is strongly associated with AR signaling 
            in prostate cancer progression. Not only was ARLNC1 induced 
            by the AR protein, but ARLNC1 stabilized the AR transcript 
            via RNA-RNA interaction. ARLNC1 knockdown suppressed AR 
            expression, global AR signaling and prostate cancer growth 
            in vitro and in vivo. Taken together, these data support a 
            role for ARLNC1 in maintaining a positive feedback loop that 
            potentiates AR signaling during prostate cancer progression 
            and identify ARLNC1 as a novel therapeutic target.}
}